Equillium (EQ)
(Delayed Data from NSDQ)
$1.55 USD
-0.01 (-0.64%)
Updated May 20, 2024 04:00 PM ET
After-Market: $1.54 -0.01 (-0.65%) 7:58 PM ET
3-Hold of 5 3
D Value F Growth F Momentum F VGM
Price, Consensus and EPS Surprise
EQ 1.55 -0.01(-0.64%)
Will EQ be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for EQ based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for EQ
Equillium, Inc. (EQ) Reports Q1 Loss, Tops Revenue Estimates
Alector (ALEC) Reports Q1 Loss, Tops Revenue Estimates
EQ: What are Zacks experts saying now?
Zacks Private Portfolio Services
5 Stocks That More Than Doubled in Q1 With More Gains Ahead
Equillium, Inc. (EQ) Reports Q4 Loss, Tops Revenue Estimates
HOOKIPA Pharma Inc. (HOOK) Reports Q4 Loss, Tops Revenue Estimates
Other News for EQ
Buy Rating Affirmed for Equillium on Milestones and Financial Prospects
Equillium Announces Interim Enrollment Achieved in Phase 3 EQUATOR Study of Itolizumab in Acute Graft-Versus-Host Disease
Equillium: Interim enrollment achieved in Phase 3 EQUATOR study for aGVHD
Buy Rating on Equillium as Promising Trials and Financial Stability Signal Upside Potential
Equillium Reports First Quarter 2024 Financial Results and Provides Recent Clinical Highlights